Search

379 Result(s)
Sort by

New African Swine Fever Manual published

New African Swine Fever Manual published

Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Positivity... just a paw away

Positivity... just a paw away

Data released by Boehringer Ingelheim shows the 96% of dog owners and 91% of cat owners claim their pet has a positive impact on their daily lives.
Global mobility

Global mobility

We are a global company with a global outlook. We welcome the breadth of perspective that international experience brings to our teams.
emperor-preserved-chmp-positive-opinion

emperor-preserved-chmp-positive-opinion

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
real-world-benefit-shown-in-T2D-treatment

real-world-benefit-shown-in-T2D-treatment

Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
commitments to sustainable development

commitments to sustainable development

On One Health Day, Boehringer Ingelheim shares an update on its strategic approach to sustainability for employees, partners and wider communities
clinical-collaboration-with-Amgen

clinical-collaboration-with-Amgen

Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
Empowering smallholder farmers

Empowering smallholder farmers

The LastMile initiative improves health equity in remote areas of Africa, increasing access to animal health resources for underserved farming communities.
2021 ABCD Young Scientist Award feline health

2021 ABCD Young Scientist Award feline health

Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their work into feline SARS-CoV-2 infections and feline leukaemia virus.
InPedILD_trial_enrollment

InPedILD_trial_enrollment

First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents